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Highlights 
 
 Opicapone is a third generation COMT inhibitor. 
 Opicapone is administered once a day. 
 Opicapone has high affinity to COMT as well as a slow dissociation constant and a 
prolonged duration of action. 
 Opicapone is a better therapeutic agent than both ENT and TOL in patients with PD 
experiencing end-of-dose-fluctuations when used in combination with L-DOPA/DDI. 
 Opicapone reduces ̈ off ̈  time and increases ̈ on¨ time.  
  The therapeutic benefits of Opicapone 50mg are maintained without dose adjustment of 











































Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) 
inhibitor that is approved for the treatment of Parkinson’s disease (PD) associated with L-DOPA 
/ L-amino acid decarboxylase inhibitor (DDI) therapy allowing for prolonged activity due to a 
more continuous supply of L-DOPA in the brain. Thus, OPC decreases fluctuation in L-DOPA 
plasma levels and favours more constant central dopaminergic receptor stimulation, thus 
improving PD symptomatology.  
Areas covered: This review evaluates the preclinical development, pharmacology, 
pharmacokinetics and safety profile of OPC. Data were extracted from published preclinical and 
clinical studies published on PUBMED and SCOPUS (Search period: 2000-2019). Clinical and 
post-marketing data were also evaluated.  
Expert opinion: OPC is a third generation COMT inhibitor with a novel structure. It has an 
efficacy and tolerability superior to its predecessors, tolcapone (TOL) and entacapone (ENT). It 
also provides a safe and simplified drug regimen that allows neurologists to individually adjust 
the existing daily administration of L-DOPA. OPC is indicated as an adjunctive therapy to L-
DOPA/DDI in patients with PD and end-of-dose motor fluctuations who cannot be stabilised on 
those combinations.  
 
Abbreviations: 3-OMD, 3-O-methyldopa; 6-OHDA, 6-hydroxydopamine; BG, basal ganglia; 
COMT, Catechol-O-methyltransferase; DDI, decarboxylase inhibitors; ENT, Entacapone; FDA, 
Food and Drug Administration; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; OPC, 
Opicapone; PD, Parkinson’s disease; TOL, Tolcapone; GDNF, Glial cell-line-derived 
neurotrophic factor; NTN, neurturin; ICV, Intracerebroventricular; PDUFA, Prescription Drug 
User Fees Act; EMA, European Medicine Administration; AE, Adverse event BG,  Basal ganglia . 

























Idiopathic Parkinson’s disease (PD) is a progressive neurodegenerative disorder clinically 
characterized by the presence of loss of motor control, slowness of movement, tremors at rest and 
rigidity [1]. Age is the most important risk factor, affecting approximately 1% of the population 
over 60 years. In addition to causing loss of motor control, patients show non-motor symptoms 
such as mood disorders, constipation, cognitive impairment, sleep disorders and difficulties with 
speech and swallowing [1-4]. Therefore, PD has generally been considered a motor disorder. The 
clinical manifestations are subject to the severity of neuron loss in the striatum region, specifically 
in the substantia nigra, resulting in neurophysiological changes in basal ganglia (BG) activity, 
which underlie the cardinal symptoms of the disease [3-5].  From a neurochemical perspective, 
there is a striatal dopamine decrease, together with neuronal loss, which is responsible for 
approximately 70% of the clinical manifestations of idiopathic PD.    
Currently the pharmacological approach to PD treatment is exclusively symptomatic. Treatment 
also varies significantly depending on the stage of the disease and patient age. However, the 
common therapeutic aim is to improve the functional situation and of patients [5-10]. There are 
several medications utilized for PD [8-10].  
Amongst the first-line drugs, L-DOPA, an endogenous dopamine precursor administered in 
association with peripheral decarboxylase inhibitors (DDI), is considered to be the most effective 
drug for motor symptoms [8-10].    
However, the problem with L-DOPA is that, over time, a high percentage of patients develop 
what is known as "motor fluctuations, ¨ an end-of-dose deterioration, or ¨wearing-off, ¨ with or 
without dyskinesias) [7-9]. The frequency of the development of these conditions varies 
depending on the age of the patient, the duration of treatment and the dose of L-DOPA used [1]. 
Progression of the disease requires that the clinician gradually increase the dose of L-DOPA to 
achieve adequate motor control. This in turn leads to the development of motor fluctuations. 




Information Classification: General 
dose deterioration and morning bradykinesia are generally the first clinical changes to appear.    
The ̈ off ̈  phase is defined as a lack of mobility (bradykinesia, akinesia, or stiffness), while during 
the ¨on¨ phase, the patient responds to L-DOPA, regardless of the presence of dyskinesias [1-4].  
Motor fluctuations, the primary side effect of long-term L-DOPA therapy, may be a consequence 
of the short half-life of oral L-DOPA. Likewise, several alterations of dopamine receptors have 
been described. These are mainly associated with the involved molecular signalling pathways. 
The modification of L-DOPA dosage and changes to its pharmaceutical formulation are the most 
common therapeutic strategies used to manage these motor fluctuations [8-13]. Increasing the 
half-life of L-DOPA helps to prevent fluctuations in plasma L-DOPA levels and increases the 
amount of L-DOPA available to the brain. 
This objective can be achieved by administering a COMT inhibitor together with L-DOPA / DDI 
therapy [14-19].  
COMT inhibitors allow a more continuous level of L-DOPA in the brain due to reduced 
fluctuation of plasma levels and more constant central dopaminergic stimulation, thus reducing 
the levels of 3-O-methyl-levodopa which may compete with L-DOPA at the blood-brain barrier. 
[16-19]. 
It has been proposed that COMT inhibitors with limited access to the brain may serve as effective 
adjunctive therapy for PD, avoiding potential undesired central side effects. ENT is currently the 
standard COMT inhibitor used in the treatment of PD.  It is well tolerated and reduces the total 
¨off ¨ time by an average of 45 minutes daily [17-20]. However, it is less efficacious than TOL, 
another COMT inhibitor.  Unfortunately, TOL may cause liver toxicity [21]. Consequently, there 
exists a need to develop new COMT inhibitors with improved therapeutic and safety profiles. [19-
21].     
In the present manuscript, the authors discuss the preclinical development of OPC, a potent 
peripheral, selective and reversible inhibitor of COMT, approved in Europe as an adjunct therapy 
with the administration of L-DOPA / DDI inhibitors in adult patients with PD who present with 
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2. Discovery strategy and preclinical development 
 
 
2.1 Introduction to Opicapone: the rationale for use in Parkinson´s disease 
 
OPC (Marketed as Ongentys, the drug was synthesized and marketed by BIAL Portela & Ca, S.A. 
Portugal) received approval for marketing authorization from the European Medical Commission 
in June 2016 as adjunctive therapy to L-DOPA/DDI in adult patients. The Food and Drug 
Administration (FDA) accepted the new drug application of OPC as a potential add-on therapy to 
L-DOPA/carbidopa for PD in April 2020. OPC is a novel third generation, highly potent, once 
daily and effective COMT inhibitor that optimizes the pharmacokinetics and bioavailability of L-
DOPA therapy. Given the safety issues with the use of TOL, OPC may be considered a safer 
alternative for PD patients that have not responded to treatment with other COMT inhibitors [14-
22]. 
Until recently, TOL and ENT were the only COMT inhibitors commercially available COMT 
inhibitors. In clinical practice, TOL was the first used, but it was withdrawn from Europe in 1998 
because there were reported cases of liver damage [23]. Nevertheless, it was reincorporated in 
European clinical practice with a mandatory control during the first year of treatment of the liver 
function.  
TOL is currently administered in PD treatment, at a dose of 100 mg three times a day, for patients 
who have not been treated with ENT. ENT is better tolerated than TOL and is administered as a 
supplement to each daily dose of L-DOPA / DDI [17-20]. This compound extends the half-life of 
L-DOPA, increasing the bioavailability of the drug and prolonging its effect. While it inhibits 
COMT centrally, ENT acts peripherally and produces a potent and reversible inhibition [14-20].  
 
2.2. Opicapone: mechanism of action 
OPC [2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-
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reversible inhibitor of COMT (Figure 1). OPC inhibits with a high affinity binding that results in 
a slower rate of complex dissociation and a longer and more constant duration of action in vivo 
(> 24 hours) [23]. This enzyme catalyzes the transfer of a methyl group from S-adenosyl-L-
methionine to substrates with a catechol group, resulting in the product of O-methylation and a 
stoichiometric amount of 5-adenosyl homocysteine [24, 25]. This reaction takes place in the 
presence of the divalent cation Mg 2+. Although the existence of O-methylation processes in 
animal tissues were observed for the first time in 1951, this enzyme was not described until 1958, 
when it was partially purified [15]. The same year, Axelrod and co-workers showed that this 
enzyme catalyzes the O-methylation of catecholamines such as dopamine and adrenaline. Studies 
carried out thereafter showed that COMT plays an important physiological role in the 
extraneuronal inactivation of endogenous catecholamines [26]. 
 In the presence of a DDI, COMT becomes the main metabolizing enzyme of L-DOPA, catalysing 
its conversion to 3-O-methyldopa (3-OMD) in the brain and the periphery. In patients taking L-
DOPA and a peripheral DDI, such as carbidopa or benserazide, OPC increases plasma L-DOPA 
levels [25, 27]. The recommended dose of OPC is 50 mg orally, given once daily at bedtime, at 
least one hour before or after the combination of L-DOPA [23, 27]. It may be necessary to adjust 
the dose of L-DOPA during the initial course of treatment with OPC, by either extending the 
treatment intervals or decreasing the dose. Although hepatotoxic effects have not been 
demonstrated, it is not recommended to administer OPC to patients with severe liver impairment, 
and caution should be taken with moderate hepatic impairment [22, 23, 25, 27]. Precaution is also 
recommended in aged patients. 
 
2.3. Pharmacodynamics of Opicapone 
 
In a set of preclinical research studies in vitro and in vivo, OPC was examined for its mechanism 
of action, the affinities of binding to peripheral COMT and the effect on the availability of L-
DOPA after concomitant use with L-DOPA and DDI [28-30]. Experiments were performed in 
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treatment were published by Kiss and colleagues in 2010 [19]. They reported that dose-dependent 
inhibition of rat liver COMT is determined 3h after oral administration of increasing doses (from 
0.03 to 10 mg/kg) of OPC   in rats. In addition, OPC increased 2-fold the plasma L-DOPA levels 
at 2 h. This increase was constant and maintained over a 24 h period. The ability of OPC to deliver 
a consistent increase in L-DOPA levels over time was related to a prolonged peripheral COMT 
inhibition, suggesting a substantial advantage over the other COMT inhibitors that were on the 
market. 
Moreover, it was reported that the administration of OPC in rats (3 mg/kg, p.o.) produced an 80% 
COMT inhibition in liver and kidney from 1 to 8h post-administration. The enzyme reached 70–
86% of control values at 48 h [28-30].  
In rats, when OPC (3mg/kg, p.o.) was administered 2 and 24 h prior to L-DOPA/benserazide 
(12mg/kg, 3mg/kg), there resulted a sustained increase, for at least 24 h, of L-DOPA 
bioavailability by1.9- and 1.3-fold [28].  
Therefore, OPC increased peripheral and central bioavailability of L-DOPA in rats. Gonçalves 
and colleagues studied a 30 mg/kg dose in rats, reporting that the effect of COMT inhibit ion 
produced by OPC was rapid, within 1 h post-dosing, and nearly complete, with 97% inhibit ion, 
in erythrocytes, liver and kidney.  In addition, authors compared the duration of action of the three 
COMT inhibitors OPC, TOL and ENT [30]. In the case of OPC, at 24 h following oral 
administration, greater than 50% of COMT activity was still inhibited. In the case of TOL and 
ENT, at 12 h following administration, the percentage of liver COMT inhibition was 50% and 
15%, respectively. 
It has been also reported that OPC metabolites, BIA 9-1079, BIA 9-1103 and BIA 9-1104 were 
also shown to actively inhibit rat liver COMT, whereas BIA 9-1100 and BIA 9-3752 were inactive  
[23]. 
Bonifácio and colleagues investigated the effect of OPC on brain availability and disposition of 
L-DOPA by means of simultaneous microdialysis of the substantia nigra and other brain areas in 
cynomolgus monkey [31].  They found that erythrocyte COMT activity that was inhibited by 75%. 
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DOPA levels. At the peripheral level, animals treated with intracerebroventricular (ICV) OPC 
significantly increased two-fold the plasma L-DOPA bioavailability. Kitajima and colleagues 
examined the effect of acute and repeated administration of OPC (1, 10 and 100 mg/kg) on 
erythrocyte COMT activity in cynomolgus monkey [32, 33]. Their results showed that COMT 
activity was significantly inhibited by OPC at 10 and 100 mg/kg, with a COMT inhibition mean 
of 76.4% and 93.2% from baseline, respectively, and a maximal effect at 2 h with both doses. 
After 24 hours, COMT activity was evaluated again and results exhibited an inhibition percentage 
of 42.6% and 60.2% in both groups, respectively [32, 33]. 
In preclinical models of PD, using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in 
cynomolgus monkeys, Bonifacio and colleagues reported that OPC improved the effects of L-
DOPA/Benserazide therapy, reducing MPTP-induced PD-like symptoms, increasing L-DOPA in 
plasma and reducing plasma 3-OMD levels and erythrocyte COMT activity [34, 35] (Table 1). 
Moura and colleagues demonstrated that in a hemi-parkinsonian model of PD, achieved through 
injection of 6-OHDA, OPC administration to rats (3 mg/kg, p.o.) once daily for three consecutive 
days prior to L-DOPA/ benserazide produced an improvement in rotational behaviour [36] (Table 
1). This effect was also associated with a significant peripheral COMT inhibition in OPC treated 
animals. 
 
2.4. Pharmacokinetic profile  
 
Preclinical studies reported that following oral administration of OPC, it was rapidly absorbed, 
reaching its Tmax in less than 4 hours. The drug possesses a short half-life in plasma and binds 
strongly to rat plasma proteins (99.7%).    
The prolonged inhibition of COMT, observed in the rat and the cynomolgus monkey after OPC 
administration was not, however, due to the presence of the compound in the circulation [23, 27-
30].   
In addition, OPC is completely metabolized in the liver 8 hours after its oral administration, 
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glucuronidation and methylation) [23]. Several OPC metabolites in rodents have been reported, 
including BIA 9-1100 (methylated metabolite, inactive), BIA 9-1103 (sulfated metabolite, 
inactive), BIA 9-1106 (glucuronide metabolite, inactive) and its active metabolite BIA 9-1079 
(an amine N-oxide reduced form of OPC) [23, 37]. Rat plasma levels of BIA 9-1079 remained in 
a high relative percentage (33.6–56.5%) of total OPC, and for this reason the active metabolite 
can play an important role in contributing to the pharmacological therapeutic activity of OPC in 
rodents [38-46]. 
However, clinical studies reported that the percentage of the active metabolite BIA 9-1079 was 
less than 15 % of total OPC derivatives [47-50]. Thus, authors suggest that the potential 
contribution of the active metabolite to the therapeutic effect of OPC should be much lower than 
expected for drugs.  
The most abundant plasma peaks after a single dose of 100 mg of 14C-OPC are the metabolites 
BIA 9-1103 (sulfate) and BIA 9-1104 (methylated), representing 67.1 and 20.5% of inactive 
metabolites [23, 27]. Other metabolic pathways include glucuronidation, methylation and 
reduction. The recommended therapeutic dose in humans is 50 mg OPC once daily [23, 27].  
Other metabolites were not found in quantifiable concentrations in the majority of the plasma 
samples collected during a clinical mass balance study. BIA 9-1100 and BIA 9-3752 were 
demonstrated to be inactive. From the dose-response curves, IC50 values for rat liver S-COMT 
inhibition of 224 nM (0.09 μg/ml), 429 nM (0.17 μg/ml) and 128 nM (0.05 μg/ml) were 
determined for OPC, BIA 9 1079 and BIA 9-1104, respectively [23].  
Gonçalves and colleagues reported on pharmacokinetic studies of OPC following administration 
of single oral doses (30, 60 and 90 mg/kg) to Wistar rats [38, 43-45]. In the study, blood samples 
were collected at different times (0.5-24h). The plasma levels of OPC and its active metabolite 
(BIA 9-1079) were quantified by high-performance liquid chromatography (HPLC) with a diode-
array detector. OPC administration to rats caused a systemic increased exposure in a dose-
proportional manner and, considering the AUC0-24h values achieved, BIA 9-1079 represented 
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Loureiro and colleagues, evaluated the metabolism of OPC in the cynomolgus monkey and the 
Wistar rat after intravenous (1 mg/kg) and oral administration (10 mg/kg) of [14C]-OPC. The 
studies indicate that OPC was rapidly absorbed and distributed throughout the body in both 
species [44]. Likewise, after 5-7 days administration of [14C]-OPC in rats, more than 89.0% of 
related radioactivity was excreted.    
More than 68% of OPC and metabolite radioactivity was excreted via the biliary route in animals, 
and the same results were reported in humans. In monkeys, very low levels (less than 10%) were 
excreted by the kidneys [23. 44]. In rats and humans, renal excretion accounted for approximately 
10% and 12% of total excretion, respectively [44, 48]. This percentage of BIA 9-1106 in the urine 
suggests that kidney is not the main route of excretion for OPC and other metabolites. The authors 
concluded that OPC is mostly excreted via the biliary route. In Cynomolgus monkey and Wistar 
rats, faecal route is the main route of excretion [23]. Furthermore, there are differences between 
the formations of OPC metabolites between species [23]. 
 
2.5. Toxicologic profile  
 
One of the major concerns with the use of COMT inhibitors is hepatoxicity caused by TOL 
administration [21]. The use of TOL requires liver function monitoring, due to the risk of liver 
toxicity. At in vitro level, some pre-clinical studies demonstrated that COMT inhibitors exhibited 
several hepatotoxicity effects on mitochondrial membrane and cellular adenosine triphosphate 
(ATP) content [19, 23, 28, 29].  
By measuring mitochondrial membrane potential (MMP) and ATP production in human primary 
hepatocytes, a 50% decrease in both MMP (181 μM) and ATP (98 μM) was noted following 24 
h incubation with OPC [19, 28]. This finding suggested that OPC was a safe compound, since 
compared with TOL and ENT, it caused less reduction in both MMP and ATP levels. ENT 
depleted ATP with an IC50 of 45 μM and decreased the MMP with an IC50 of 4 μM and TOL 25 
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Thus, these data give support to the low hepatotoxic effects of OPC. Taking into account these 
data, no liver toxicity concerns were expected with the dosing regimens tested in preclinical 
studies. 
The same research team examined the toxicity of the three COMT inhibitors in HepaRG cells, 
measuring ATP depletion (indicator of cell viability), caspase 3/7 activation (indicator of 
apoptosis), glutathione depletion (indicator of reactive metabolite formation) and loss of the 
mitochondrial membrane potential (mitochondrial dysfunction) [51]. In HepaRG cells, increasing 
concentrations of OPC, ENT or TOL produced a progressive decrease in MMP, with IC50 values 
of 0.5 mM, 1.0 mM and 0.1 mM, respectively. Determination of ATP content in these samples 
revealed no toxicity effect at any of the tested concentrations for OPC or ENT, but at 200 µM a 
decrease in ATP content was observed for TOL [51]. COMT inhibitors at 30 µM, 100 µM or 200 
µM did not increase caspase 3 activity. In terms of oxidative stress, the only significant decrease 
in glutathione levels occurred at 200 µM (28% of control values) of TOL. Since OPC did not 
decrease ATP cellular levels or increase apoptosis, nor did it lead to oxidative stress in human 
cell line HepaRG [23, 51], it was deemed to be a safe compound in terms of liver toxicity.   
 
Lopes and collaborators confirmed the results obtained at pre-clinical studies in a multicentre, 
double blind, randomised, placebo- and active-controlled study (BIPARK II and I). In this study 
509 total subjects were treated with OPC (25 or 50 mg) and 257 with placebo. They concluded 
that there were no relevant differences between OPC and placebo group in the parameters 
associated with liver laboratory toxicity [52-54]. Moreover, no significant cardiovascular effects 
were observed in dogs, with the exception of a slight shortening in the QT interval observed at 
600 mg / kg.  No effect on action potential parameters was noted. 
In vitro studies showed low cardiac toxicity with high dose OPC [23, 55, 56].  Pinto and 
colleagues evaluated the effects of OPC on cardiac repolarization in healthy adult volunteers. At 
the evaluated doses of OPC in the study (50 and 800 mg), no adverse effects on electrocardiogram 
intervals were observed [55, 56]. Thus, OPC has a negligible cardiac toxicity risk in preclinical 
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Castro-Caldas and colleagues reported data from human clinical studies showing that OPC 
adverse events induced by COMT inhibitors are associated with an increase in dopaminergic and 
non-dopaminergic stimulation [57]. The most common side effects were due to dopaminergic 
potentiation, since the main objective of OPC is to increase the bioavailability and supply of 
dopamine to the brain. The most frequent adverse events associated with OPC treatment, 
dyskinesias and nausea, were found to be mediated by dopaminergic stimulation, independent of 
dose, and tended to decrease over time. Side effects could be minimized by increasing dose 
intervals or by reducing the total dose of L-DOPA. The authors concluded that OPC shows a 
favourable safety profile, it is well-tolerated and adverse reactions are similar to those described 
for ENT [57].  
In summary, preclinical studies suggest that OPC is a safe and well-tolerated drug which 
possesses a reduced risk of hepatic and cardiac toxicity, and adverse reactions are in line with 
those described for ENT [23].  
 
 Clinical findings  
 
Two-phase III clinical trials (BIPARK-I, also known as BIA-91067-301, and BIPARK-II, also 
known BIA-91067-302). Multicentre, randomized, double-blind, placebo-controlled trials were 
presented for drug approval [58-68].   
The European Commission approved OPC under the brand name Ongentys®, an adjunct therapy 
to L-DOPA/DDI in adult patients with PD and end-of-dose motor fluctuations which cannot be 
stabilized on L-DOPA/DDI alone. [23]. BIPARK-I evaluated the efficacy and safety of OPC at 
5, 25 and 50 mg, administered once daily, in comparison with ENT (200 mg) or placebo [58, 62, 
65, 67, 68, 69] (Table 2).  OPC 50 mg once a day (QD) achieved the same therapeutic effects as 
ENT, and was found to be superior to placebo [58, 69].    
The study included 600 patients from 106 study centers in Europe. Patient criteria were as follows: 
The patients were aged between 34 and 83 years old and carried the diagnosis of idiopathic PD 
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subjects had received optimal treatment with L-DOPA and had been clinically stable for at least 
4 weeks. Signs of end-of-dose deterioration were present for at least 4 weeks, with an average of 
daily ¨off ̈ time of 1.5h, excluding AM periods prior to the first daily dose. Finally, subjects were 
required to demonstrate an ability to keep a precise 24-hr diary [58].   
The study showed that the OPC-treated patients experienced an increase in average total ¨on ̈ time 
of 119 minutes, as compared with 47.1 minutes in the placebo group, a statistically significant 
difference [58, 67, 69]. Most of the time gained referred to the period in which the patient 
experienced non-problematic dyskinesia, without a significant gain in the ¨on ¨time with 
problematic dyskinesia [58] (Table 2). 
BIPARK-11 (BIA-91067-302) included 427 patients, randomly assigned to OPC 25mg and 50 
mg treatment dose groups [59]. At the end of this period, subjects entered an open phase of OPC 
treatment of 67 weeks. Of 427 subjects involved in this study, 376 patients completed the double-
blind phase. The 50mg group had a greater number of ¨off ¨and ¨on¨ time responders compared 
with placebo.  At 25 mg, OPC effectively increased the percentage of responders in ¨on¨ time. 
However, with regards to ¨off ̈ time response, the 25mg OCP group fared no better than placebo.  
With regards to the absolute change in ¨on¨ time, significant differences were observed in the 
50mg treatment group compared to placebo (52.59 min). No significant differences were noted 
between treatment and control groups when considering ¨on¨ time without dyskinesia or 
troublesome dyskinesia [59 
The most frequently observed adverse effects related to treatment were: dyskinesia (7.6% - 24% 
in OPC, 8.2% in ENT, 4.1% -8.1% in PLA), L-DOPA constipation (0.9%, -6% in OPC, 4.1% in 
ENT, 1.5% -2.5% in placebo), insomnia (1.3% - 8% in OPC, 5.7% in ENT, 0.8% - 2.2% in PLA), 
dry mouth (1.6% -10.4% in OPC, 1.6% in ENT, 0.7% -1.7% in placebo), increased creatine 
phosphokinase (CPK) (0.9% -8% in OPC, 0.8% in ENT, 0% -3.7% in PLA), and dizziness (1.6% 
-5% in OPC, 4.1% in ENT, 0 , 8% -1.5% in PLA) [23, 27, 59, 70-74].  
OPC treatment effectively reduced ¨off ¨ time and increased ¨on ¨ time without increasing the 
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increasing the dose of L-DOPA [23, 27, 53, 59].  50mg OPC daily is thus considered the most 
efficacious dose, providing an average of one additional hour of ¨off ¨time reduction [53]. 
 
4. Post-launch of Opicapone 
In June 2016, the EMA approved the new drug Ongentys® (OPC) for oral treatment of PD adult 
patients with motor fluctuations [23, 27]. OPC has been launched in the United Kingdom, 
Germany, Portugal and Spain, and it is expected that, between 2020 and 2021, it will be 
introduced in other European countries as well as the United States, China and Japan. In February 
2017, BIAL and Neurocrine Biosciences, Inc. announced that they had entered into a licensing 
agreement for the development and commercialization of OPC in North America. Recently, the 
FDA accepted OPC for PD (co-adjuvant) as a complementary treatment to L-DOPA / carbidopa 
in patients with ¨off ¨ episodes. Likewise, a 12-month review process was established which will 
be detailed in, the Prescription Drug User Fees Act starting April 2020.  
In April 2013, Ono Pharmaceutical entered into a license agreement with BIAL for the Japan 
market. In February 2019, Ono Pharmaceutical submitted an application for manufacturing and 
marketing approval of OPC. In January 2018, BIAL and Jiangsu Wanbang Biopharmaceutical 
Group Co., Ltd. announced that they had entered into a license agreement for the 
commercialization of OPC in China. OPC is available as hard capsules (25 and 50 mg), and is 
taken once daily at bedtime, at least 1 hour before or after L-DOPA. 
   
4.1. Post-marketing data 
A phase 4 clinical trial (NCT02847442, OPTIPARK) is currently ongoing in the European Union, 
aiming to explore the potential safety and tolerability of OPC 50 mg during a period of 3 months 
among 518 PD patients with end-of-dose motor fluctuations. This is a prospective, open-label, 
single-group, multi-centre trial in PD patients with wearing-off motor fluctuations. However, still 
long-term studies are still needed to ensure the safety profile and demonstrate the advantage of 
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4.2. Safety and pharmacovigilance  
 
The safety, efficacy and tolerability of OPC was evaluated over the course of a year in the 
open extension phase [53, 75] (Table 2). To perform this study, patients who completed the 
double-blind part of the BIPARK II study were enrolled in an open 1-year extension phase. Pooled 
analyses of the double-blind and open-label stages of BIPARK I and II have been carried out. 
During this extension phase, two groups were studied. Patients that had previously taken placebo 
or ENT were started on 50mg OPC.  The second group, having previously taken 50mg OPC, were 
continued on the same dose [53, 75].   
The extension period data were analysed with the aim of elucidating the long-term effects of 
OPC. To date, two studies based on the extension phase data have been published. Looking at 
data generated from both the double-blind and the open BIPARK 1 and 2 studies, Lees and co-
workers aimed to evaluate the safety and tolerability of adjunct OPC (25 and 50mg) in PD patients 
treated with L-DOPA. 
The majority of adverse events were mild or moderate in severity and generally transient and 
manageable, as indicated by the low interruption rate. Long-term use of OPC, once a day for 1 
year at a dose of 25 mg or 50 mg, does not appear to result in any new or unexpected safety 
problems.  
At 50mg OPC daily, no evidence for hepatic injury was noted.  Furthermore, side effects that 
had been reported with both TOL and ENT, such as severe diarrhoea, were not found.  The 
percentage of patients who interrupted the treatment due to adverse events mediated by OPC was 
low and similar in all treatment groups [53]. 
In a similar study carried out by Ferreira and colleagues, the same population groups were 
evaluated at doses of both 25 and 50mg OPC. Significant improvements in motor fluctuations 
were noted in the study groups, without a significant increase in dopaminergic side effects such 
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In addition, it was observed that when switching from placebo to OPC in the extension phase, the 
¨off ̈  time was reduced by an average of 51.1 minutes. During the double-blind phase, a one-year 
follow-up showed that patients previously treated with OPC at 25 and 50mg demonstrated an 
average ̈ off¨ time reduction of 35.1 minutes and 58.1 minutes, respectively, with a total ¨off ̈ time 
reduction average of nearly 2 hours per day. 
With regard to ¨on¨ time, in the patients originally receiving placebo, there was an average 
increase of 52.5 minutes, but no change in those patients that initially received 50mg OPC. 
The most frequent side effect observed was dyskinesias at 16% in the treatment group.  
 
4.3. Studies on market and main competitors  
Currently, two COMT inhibitors, ENT and TOL, remain on the market for the treatment of PD. 
While ENT is a safe product which is given several times a day, TOL requires close monitoring 
due to the potential risk of hepatotoxicity. However, TOL is more potent than ENT.  
 
OPC is currently marketed under the Ongentys® brand name in the United Kingdom, Germany, 
Spain, Italy and North America. Under the terms of the agreement, Neurocrine will be responsible 
for development and commercialization of OPC in the United States and Canada. Bialis launched 
OPC in EU market in 2018. In its first year, sales of OPC in the PD market are projected to have 
reached $3.7million. By 2022, global sales are projected to increase to $68.6 million [76, 77].  
However, there are some drawbacks which could slow down the OPC growth in pharmaceutical 
market of PD treatments such as competition with Stalevo®.  
Stalevo® is a combination of L-DOPA / carbidopa in the same pill with production costs that are 





PD is a devastatingly progressive disease with only symptomatic therapy currently available.  
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binding affinity, which results in a slow rate of dissociation of the complex and a long duration 
of action that allows once daily administration [78]. Preclinical studies reported that OPC, 
compared to other COMT inhibitors, is safe and the observed adverse effects are lower, especially 
with respect to hepatoxicity and cardiotoxicity [23-36] (Table 1).  
In addition, in animal studies it has been observed that the active metabolite BIA 9-1079 
contributes to the therapeutic effect, which does not occur in humans. 
Moreover, preclinical data in rat and monkey models demonstrate that OPC enhances 
significantly the bioavailability of L-DOPA [23, 40-45]. In both MPTP and 6-OHD-induced PD 
animal models a significant improvement of movement-related disease symptoms can be 
demonstrated when OPC is used as an adjunct with L-DOPA / DDI.  Preclinical results indicate 
that OPC is an effective compound with suitable pharmacokinetics, a potent inhibitor of COMT 
which produces few side effects. 
Results of two-phase III studies conducted in patients with PD demonstrated a significant 
reduction in ¨off ¨ time following administration of 50 mg OPC as well as increased ¨on¨ time 
(Table 2).   The BIPARK-I study also showed greater efficacy of OPC over ENT [58].  OPC 50 
mg appears to demonstrate a greater effect on ̈ off ̈  time reduction suggesting a potentially greater 
clinical benefit.   
 The BIPARK-2 study confirms the presence of fewer adverse effect such as diarrhoea, a side 
effect characteristic of COMT inhibitors [59].  As suggested by the low rate of patient withdrawal 
due to side effects, OPC appears to be well tolerated. 
When compared to other COMT, OPC is administered once daily, one hour before or after 
administration of L-DOPA, while ENT is administered up to 8 times a day along with L-DOPA. 
Inasmuch as L-DOPA may be taken multiple times a day, the QD dosing of OPC does not 
necessarily simplify the dosing regimen. Presently an ENT/L-DOPA/DDI inhibitor combination 
tablet is available, facilitating dosing [79-82]. TOL is administered three times a day, but due to 
potential hepatotoxicity, TOL is recommended only for those patients unable to tolerate or have 
poor clinical response to ENT or OPC. In patients with mild hepatic impairment, OPC may be 
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 Given the safety issues with the use of TOL, OPC may be considered a safer alternative in 
patients who have not responded to treatment with ENT. 
6. Expert opinion 
 
Ideal treatment of PD would be to modify the course of the illness, but currently no such treatment 
exists.  
Different strategies have been proposed to treat PD. For example, based upon the observation that 
mitochondrial dysfunction and oxidative damage may play a role in the pathogenesis of PD, a 
study (clinicaltrials.gov Identifier: NCT00740714) examined the effectiveness of treatment with 
2400mg CoQ10 in idiopathic PD. However, in phase III clinical trials, although was safe and well 
tolerated by patients, patients did not show significant clinical improvement [83]. 
It has been observed that the CNS of PD patients contain abnormal clumps of the protein alpha-
synuclein. It has been proposed that this protein forms an extracellular neurotoxin implicated in 
the pathogenesis of PD. A monoclonal IgG1 antibody, PRX002 / RG7935, has been designed to 
attack the C-terminal of neurotoxic aggregate forms of α-synuclein and reduce their levels in the 
brain [84]. A phase 1 clinical trial utilizing intravenous infusions of PRX002V 
(ClinicalTrials.govIdentifier:NCT02157714) has shown acceptable safety profiles, and a phase 2 
trial is now underway, with completion in 2021 (NCT03100149) [84, 85]. 
 
Another strategy used to modify or delay the disease has been the use of neurotrophic growth 
factors such as glial cell-line-derived neurotrophic factor (GDNF) and neurturin (NTN), which 
are members of the transforming growth factor β superfamily [86]. The objective of these 
strategies is to restore the viability of degenerated neurons.  A clinical trial (ClinicalTrials.gov, 
number NCT00985517) has been conducted based on the direct administration of the gene therapy 
of an AAV2-neurturin vector (CERE-120) in the brain (to the putamen plus substantia nigra) [86-
88]. However, the phase 2 was discontinued because the compound did not demonstrate 
statistically significant efficacy for an improvement in patient scores according to the Unified 
Parkinson’s Disease Rating Scale. Glial derived neurotrophic factor (GDNF) was also developed 
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satisfactory, but the authors suggest hopes for longer GDNF treatments that it is possible to restore 
damaged cells in PD [89, 90]. Trophic factors may represent a future PD treatment, however this 
approach has not met with great success [88].  
Since there is no cure for PD, the objective of the treatment consists of controlling the motor 
symptoms primarily through administration of L-DOPA/DDI and improving the quality of life of 
patients [2-4]. Although L-DOPA improves the control of PD symptoms, it is not able to halt 
disease progression, and, furthermore, the beneficial effects of L-DOPA eventually wear off, 
leading to worsening of symptoms and the appearance of motor fluctuations in patients.  
In the presence of a DDI inhibitor, COMT becomes the main metabolizing enzyme of L-DOPA, 
catalysing its conversion to 3-O-methyldopa (3-OMD) not only in the brain but also in the 
periphery. OPC is a peripheral, selective and reversible inhibitor of COMT with a high binding 
affinity that results in the slowing in the rate of complex dissociation leading to a long and 
constant duration of action in vivo (> 24 hours). In patients taking L-DOPA and a DDI, OPC 
significantly improves PD symptomology increasing plasma L-DOPA levels in the CNS. Thus, 
OPC provides a suitable strategy that could well accommodate the therapeutic needs of PD 
patients.   
An important challenge in PD treatment is to minimize the ¨off ¨ time and to increase the ¨on¨ 
time, a property related to the efficacy and the pharmacokinetic properties of the drug. In the 
absence of disease-modifying treatments, the therapeutic strategy is based on improving treatment 
with L-DOPA by enhancing the ¨on ¨ phenomenon and decreasing the ¨off¨ effect. As 
demonstrated by clinical trials, the latter has been ameliorated with the administration of OPC 
[53-75]. 
 
Before OPC approval for the treatment of PD, only two COMT inhibitors were available for 
clinical L-DOPA/DDI association for the management of end-of-dose motor fluctuations: TOL 
and ENT. TOL was the first COMT inhibitor to be commercially available and it is a more potent 
COMT inhibitor than ENT, both in the periphery and CNS [20-23]; however, it has also been 
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function monitoring and must be restricted to patients who have failed to respond, or those 
patients that are intolerant to other COMT inhibitors. Conversely, ENT acts only in the periphery 
and is safer than TOL but has limited efficacy as well as a low to moderate oral bioavailability, 
which requires frequent dosing [76, 77]. 
Accordingly, OPC represents an improvement in the treatment of PD compared to the other 
COMT inhibitors. The beneficial effects of OPC in PD therapy are currently thought to be due to 
a) dosing regimen, since it is administered once a day, b) lack of hepatotoxicity compared with 
TOL (ENT is not associated with hepatotoxicity, therefore, it does not require liver monitoring), 
c) higher mean reduction of ¨off ̈  time, with an average reduction of 116.8 min at the therapeutic 
dose of 50mg OPC.  
Furthermore, ENT has the disadvantage of low oral bioavailability with a shorter duration of 
action as well as being less potent. 
At the recommended therapeutic dose of 200 mg, ENT therefore has limited clinical efficacy [79, 
80]. OPC meets the need for a safer, more potent and long-acting COMT inhibitor [80]. As a 
selective COMT, reduction in ¨off ¨ time provides a new strategy that could well accommodate 
the therapeutic needs of PD patients.  A small molecule such as OPC demonstrates proven 
advantage over medicines previously used for idiopathic PD and are welcome in the marketplace.   
Of course, OPC represents symptomatic treatment of PD; a curative or preventative approach 
remains elusive.  
In conclusion, despite its limitations, OPC constitutes a paradigm shift in the treatment of PD.  It 
may represent a starting point for both a better understanding of PD ś pathogenesis as well as the 
development of new types of medical and pharmaceutical interventions to improve care for PD 
patients.    
However, improvements in the design of COMT inhibitors should still be pursued, including, for 
example, an improved half-life and low toxicity whilst maintaining or increasing drug efficacy. 
COMT inhibitors currently marketed (with the exception of TOL) are intended to act exclusively 
in the inhibition of peripheral COMT. We strongly believe that it would be of interest for new 
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Figure 1. The co-administration of L-DOPA / DDI with OPC (peripheral COMT inhibitor), 
allows a more continuous supply of L-DOPA in the brain. Therefore, OPC improves the 
symptomatology of PD by decreasing fluctuations in plasma levels of L-DOPA and favoring a 
constant stimulation of the central dopaminergic receptor by increasing brain dopamine levels. 
 
 
